Form 4: Director Boylan Receives 90,000 CMPX Stock Options

Compass Therapeutics Director James P. Boylan was granted 90,000 stock options with an exercise price of $5.17, vesting by mid-2026.

Summary

• Director James P. Boylan of Compass Therapeutics, Inc. (CMPX) was granted 90,000 stock options.
• The options have an exercise price of $5.17 per share.
• The grant date for these options was January 2, 2026.
• The options vest in full upon the earlier of June 10, 2026, or the date of the next annual meeting of the Company's stockholders.
• The options have an expiration date of January 2, 2036.
• Mr. Boylan is obligated to transfer any securities issued under these options, or their economic benefit, to Enavate Sciences, LP, of which he is a member.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice aimed at aligning interests. While not a direct indicator of operational performance, it reflects ongoing director involvement and a long-term incentive structure. The obligation to Enavate adds a layer of complexity but doesn't fundamentally alter the nature of the grant.

Positives

• The grant of 90,000 stock options to a director indicates continued alignment of management interests with shareholder value.
• The long expiration date (January 2, 2036) provides ample time for the stock price to appreciate above the exercise price of $5.17.

Negatives

• The options are not immediately exercisable, requiring a vesting period until mid-2026.
• The obligation to transfer the economic benefit to Enavate Sciences, LP, means the direct personal financial incentive for Mr. Boylan is indirect.

Risks

• The value of the stock options is contingent on the market price of Compass Therapeutics, Inc. common stock exceeding the exercise price of $5.17.
• There is a risk that the vesting conditions (June 10, 2026, or next annual meeting) may not be met, though this is unlikely for time-based vesting.
• Future stock price performance is uncertain, and the options could expire worthless if the stock price remains below the exercise price.

Future Outlook

Not applicable, as this Form 4 filing reports a past transaction and does not contain forward-looking statements or guidance.

Industry Context

This is a standard equity grant for a director in a publicly traded company, common in the biotechnology sector to align leadership incentives with long-term company performance. The specific terms (exercise price, vesting) are typical for such grants.

Comparison to Industry Standards

• The grant of stock options to a director is a common form of executive and director compensation across industries, including biotechnology, aligning their interests with shareholder value.
• An exercise price set at the market price on the grant date ($5.17) is standard for incentive stock options.
• The vesting schedule, tied to a specific date or the next annual meeting, is a typical mechanism to ensure continued service and performance.
• The 10-year expiration period (until January 2, 2036) is also a common duration for stock options, providing a long-term incentive.

Related Party Transactions

• The reporting person, James P. Boylan, is a member of Enavate Sciences, LP.
• Mr. Boylan is obligated to transfer any securities issued under these stock options, or the economic benefit thereof, to Enavate Sciences, LP.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution if exercised, but it also aligns a director's interests with long-term share price appreciation.
• Management/Directors: Provides a long-term incentive for Director Boylan, linking his compensation to the company's stock performance.

Next Steps

• The options will vest upon the earlier of June 10, 2026, or the date of the next annual meeting of the Company's stockholders.
• Mr. Boylan will be obligated to transfer any securities or economic benefits from these options to Enavate Sciences, LP upon exercise.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to a director, which is a standard compensation practice. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grant aligns director interests with long-term shareholder value but does not present a catalyst for immediate stock price movement. Investors should continue to hold based on broader company fundamentals and market conditions, not solely on this compensation disclosure.

Keywords

Compass Therapeutics, CMPX, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Biotechnology, Enavate Sciences